Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine extended-release formulations in schizophrenia
NCT06319170Phase 1Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olanzapine in schizophrenia and schizoaffective disorder (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Maximum Observed Plasma Concentration of Olanzapine (Extended-release Formulation) at 84 days, Area Under the Plasma Concentration-time Curve From Study Drug Administration to the Last Measurable Concentration of Olanzapine (Extended-release Formulation) at 84 days and 1 more. Started Mar 2024; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT06319170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319170.